Dulaglutide
Also known as: Trulicity
GLP-1 receptor agonist fused to modified IgG4-Fc; long-acting weekly injection enhancing insulin and suppressing glucagon.
- Typical dose
- 750 mcg – 4.5 mg
- Frequency
- once weekly
- Route
- Subcutaneous
- Half-life
- 5 days
- Routes
- Subcutaneous
- Status
- FDA-approved for T2 diabetes
Benefits
- Weekly dosing convenience
- A1C reduction
- Weight loss
- Cardiovascular risk reduction
Dosing
A common research range for Dulaglutide is 750 mcg to 4.5 mg once weekly. Start 0.75mg weekly, titrate to 1.5-4.5mg. These figures are reference points from published literature, not a prescription — your protocol should be set with a licensed provider.
Half-life
Dulaglutide has an approximate half-life of 5 days. Vial can display informational half-life estimates when supported data is available. These estimates are not measured blood concentrations or dosing instructions.
Storage
2-8°C; single-use pen.
Reported side effects
- GI distress
- Nausea
- Diarrhea
- Decreased appetite
Contraindications
- MEN2
- Medullary thyroid carcinoma
- Pancreatitis
Track Dulaglutide with Vial
Vial logs every Dulaglutide dose, organizes your schedule, and offers reconstitution math and supported half-life estimates. Tracking records stay on your device. A Vial Pro subscription is required. Download Vial on the App Store →
This page is for educational and harm-reduction purposes only. Dulaglutide is not FDA-approved for most uses described here. Always consult a licensed physician before starting any peptide protocol. Vial does not sell peptides, recommend vendors, or provide medical advice.